# The Antigen-Specific Immunotherapy Landscape ## A Patient-Centered Market Report, with Strategic Implications for an EoE Peptide-MHC (pMHC) Vaccine *Prepared as part of a patient-centered EoE therapeutic-development program.* *Tzield (teplizumab) serves as the FDA-approved precedent and post-market case study.* --- > ### A note on why this report is written the way it is > This report is written by and for people who believe patients belong in > therapeutic development at every stage. Every program profiled here treats a > disease that someone lives with daily. Where the evidence lets us, we center > what patients said, felt, and needed — not as an appendix, but as a lens on > whether each program was built for the people it was meant to serve. The > author of the underlying program is herself an EoE patient; that perspective > is a design input, not a disclaimer. > ### A note on the colour of this report > The magentas and purples running through these pages are not decoration. In > pathology, eosinophils — the cells that define eosinophilic esophagitis — are > identified by the **eosin** stain, which renders their granules the vivid > rose-magenta a clinician sees down the microscope; **hematoxylin** counterstains > nuclei a deep purple. This report borrows that hematoxylin-and-eosin (H&E) > palette so that the visual identity of the disease is present on every page. > Where a third colour was needed for clarity, we chose a special-stain gold. The > scheme is also colour-vision-deficiency safe. --- ## Executive Summary **The opportunity.** Antigen-specific immunotherapy — teaching the immune system to tolerate a specific trigger rather than broadly suppressing it — has produced exactly one FDA-approved agent (Tzield/teplizumab, for delaying type 1 diabetes) and a field of instructive successes and failures across celiac disease, T1D, multiple sclerosis, and rheumatoid arthritis. **No true peptide-MHC (pMHC) therapeutic has yet demonstrated clinical efficacy in any disease, and none exists for eosinophilic esophagitis (EoE).** That is the whitespace this program targets. **What we found (five headline findings):** 1. **Approval was won on strategy, not specificity.** Tzield — the only approved agent — is antigen-*nonspecific*. It succeeded by redefining the population (at-risk, presymptomatic) and the endpoint (delay of onset, not cure), a regulatory template far more transferable to EoE than its mechanism. 2. **The flagship celiac failure (Nexvax2) is the field's most valuable lesson.** It bet a three-peptide vaccine against a symptom endpoint in established disease, and the peptide (being gluten itself) reproduced the very symptoms it measured. Programs that instead led with a pharmacodynamic tolerance biomarker and a tolerogenic delivery context (TAK-101, KAN-101) advanced. 3. **A failed antigen was rescued by precision medicine.** GAD-alum missed its Phase 3 endpoint, then found new life through HLA-DR3-DQ2 patient stratification and a changed delivery route — a direct template for HLA-stratified EoE design. 4. **Tzield's post-market experience shows the access bottleneck is screening, not demand.** At ~$194,000 per course with universal prior authorization, uptake (~1.2% of the T1D drug market in 2023) is gated by the absence of routine autoantibody screening — a warning that an EoE vaccine must co-build its companion-diagnostic pathway. 5. **Patient voice arrived too late, everywhere.** No formal patient-experience event (PFDD or equivalent) demonstrably preceded the program it might have shaped; EoE has no dedicated PFDD at all. This is the sequence an EoE patient-led program can, uniquely, invert. **The strategic thesis.** An EoE pMHC vaccine can be the first true peptide-MHC therapeutic to pursue clinical proof-of-concept, in an indication with no antigen-specific competitor. Its odds are maximized by copying the winners (validated tolerance biomarker; tolerogenic, non-reactogenic delivery; HLA/sensitization stratification; early-disease progression-prevention endpoint; co-built screening) and avoiding the losers' mistakes — and, above all, by capturing patient needs, interest, and concerns *before* the trial is designed. The follow-on EoE patient survey (Section 10) is the first step. --- ## 1. Methodology & Data Sources - **Trial architecture:** programmatic harvest of ClinicalTrials.gov API v2 (59 core relevant trials across 8 clinical-stage programs; full design fields, outcomes, and termination reasons). See `trials_master.csv`. - **Scientific origins:** literature reconstruction via OpenAlex and CrossRef; 17 pivotal references, **all DOIs validated to resolve against CrossRef**. See Appendix B and `citation_library_final.json`. - **Trial outcomes:** pivotal-endpoint coding into a comparative matrix (`outcomes_matrix.csv`). - **Post-market:** FDA, SEC filings (Sanofi/MacroGenics), payer policy documents, and reimbursement reviews (CDA-AMC), via targeted web search. - **Patient voice & PRO:** peer-reviewed PRO/HRQoL instrument literature, patient organization materials (APFED, iCureCeliac, JDRF/Breakthrough T1D), and FDA disease-specific guidance. See `pro_instruments.csv`. - **PFDD:** FDA PFDD/EL-PFDD program records and Voice-of-the-Patient reports. See `pfdd_inventory.csv`. - **Scope:** antigen-specific immunotherapy (broad) — peptide/epitope vaccines, tolerogenic nanoparticles, pMHC nanoparticles, antigen+adjuvant — plus Tzield as the approved anti-CD3 precedent. Adjacent modalities (tol-DC, CAAR-T) noted as context. - **Accuracy discipline:** all DOIs CrossRef-verified; trial IDs traced to CT.gov records; dates that could not be verified are explicitly marked approximate; the T1D/celiac PFDD status was corrected against the FDA-led 24-disease series list. --- ## 2. Field Primer — what "antigen-specific tolerance" and pMHC mean **The core idea.** In autoimmune and allergic disease, a subset of T cells recognizes a specific antigen (a self-protein, a food, or gluten) and drives inflammation. Conventional therapy suppresses immunity broadly, with infection and cancer risks. **Antigen-specific immunotherapy** aims to switch off *only* the disease-driving clones — by anergizing them, deleting them, or converting them into regulatory cells — leaving the rest of the immune system intact. **How a T cell "sees" antigen: the peptide-MHC (pMHC) complex.** T cells do not recognize whole proteins. Antigen-presenting cells chop proteins into peptides and display them in the groove of a Major Histocompatibility Complex (MHC, called HLA in humans) molecule. The T-cell receptor reads this **peptide-MHC (pMHC) complex**. Which peptides a person presents depends on their HLA genotype — which is why HLA stratification recurs throughout this landscape. **The modality ladder (low → high mechanistic fidelity to a pMHC vaccine):** 1. **Anti-CD3 (Tzield):** blocks the T-cell receptor complex generically — no antigen specificity. The approved precedent. 2. **Antigen + adjuvant (GAD-alum):** whole autoantigen with an immune-deviating adjuvant. 3. **Peptide / nanoparticle vaccines (Nexvax2, TAK-101, KAN-101):** deliver the defined peptide(s), optionally in a tolerogenic carrier. 4. **pMHC complex (Navacim; the EoE concept):** present the peptide *already loaded on MHC*, the most direct way to engage exactly the cognate T cells — the truest "pMHC vaccine," validated preclinically but not yet clinically. **Why celiac and T1D led the field:** both offered what EoE must engineer — a defined antigen and a measurable T-cell/biomarker readout. EoE's plural, patient-variable food allergens are the central scientific challenge the rest of this report returns to.